Yang XH - Search Results

1

[Effects of a protein kinase C inhibitor combined with cisplatin on non-small cell lung cancer].

Gao ZQ, Han BH, Sha HF, Shi ZY, Yang XH, Feng JX. Gao ZQ, et al. Among authors: yang xh. Zhonghua Jie He He Hu Xi Za Zhi. 2010 Apr;33(4):284-8. Zhonghua Jie He He Hu Xi Za Zhi. 2010. PMID: 20646461 Chinese.

2

Comparative proteomic analysis of paclitaxel sensitive A549 lung adenocarcinoma cell line and its resistant counterpart A549-Taxol.

Sun QL, Sha HF, Yang XH, Bao GL, Lu J, Xie YY. Sun QL, et al. Among authors: yang xh. J Cancer Res Clin Oncol. 2011 Mar;137(3):521-32. doi: 10.1007/s00432-010-0913-9. Epub 2010 May 25. J Cancer Res Clin Oncol. 2011. PMID: 20499251

3

[Prognostic Analysis of ERCC1, RRM1 and p53 Expressions in Postoperative Stage I-II Lung Cancer.].

Wang H, Feng J, Zhang X, Yang X, He W, Sha H, Han B. Wang H, et al. Zhongguo Fei Ai Za Zhi. 2009 May 20;12(5):387-95. doi: 10.3779/j.issn.1009-3419.2009.05.003. Zhongguo Fei Ai Za Zhi. 2009. PMID: 20719132 Free article. Chinese.

4

[Analysis of differential gel electrophoresis of paclitaxol resistant and sensitive lung adenocarcinoma cells' secretome.].

Sun Q, Yang X, Lu J, Xie Y, Chu T, Sha H. Sun Q, et al. Zhongguo Fei Ai Za Zhi. 2009 Jul 20;12(7):735-40. doi: 10.3779/j.issn.1009-3419.2009.07.001. Zhongguo Fei Ai Za Zhi. 2009. PMID: 20719147 Free article. Chinese.

5

Establishment of a biomarker model for predicting bone metastasis in resected stage III non-small cell lung cancer.

Zhou Z, Chen ZW, Yang XH, Shen L, Ai XH, Lu S, Luo QQ. Zhou Z, et al. Among authors: yang xh. J Exp Clin Cancer Res. 2012 Apr 26;31(1):34. doi: 10.1186/1756-9966-31-34. J Exp Clin Cancer Res. 2012. PMID: 22537906 Free PMC article.

6

Proteome analysis and tissue array for profiling protein markers associated with type B thymoma subclassification.

Sun QL, Fang WT, Feng J, Zhang J, Yang XH, Gu ZT, Zhu L, Sha HF. Sun QL, et al. Among authors: yang xh. Chin Med J (Engl). 2012 Aug;125(16):2811-8. Chin Med J (Engl). 2012. PMID: 22932072

7

EGFR phosphorylates and inhibits lung tumor suppressor GPRC5A in lung cancer.

Lin X, Zhong S, Ye X, Liao Y, Yao F, Yang X, Sun B, Zhang J, Li Q, Gao Y, Wang Y, Liu J, Han B, Chin YE, Zhou BP, Deng J. Lin X, et al. Mol Cancer. 2014 Oct 14;13:233. doi: 10.1186/1476-4598-13-233. Mol Cancer. 2014. PMID: 25311788 Free PMC article.

8

Lung adenocarcinoma resistance to therapy with EGFR‑tyrosine kinase inhibitors is related to increased expression of cancer stem cell markers SOX2, OCT4 and NANOG.

Hu F, Li C, Zheng X, Zhang H, Shen Y, Zhou L, Yang X, Han B, Zhang X. Hu F, et al. Oncol Rep. 2020 Feb;43(2):727-735. doi: 10.3892/or.2019.7454. Epub 2020 Jan 2. Oncol Rep. 2020. PMID: 31894290

9

Micropapillary pattern is associated with the development of brain metastases and the reduction of survival time in EGFR-mutation lung adenocarcinoma patients with surgery.

Li C, Shen Y, Hu F, Chu T, Yang X, Shao J, Zheng X, Xu J, Zhang H, Han B, Zhong H, Zhang X. Li C, et al. Lung Cancer. 2020 Mar;141:72-77. doi: 10.1016/j.lungcan.2020.01.007. Epub 2020 Jan 10. Lung Cancer. 2020. PMID: 31955003 Clinical Trial.

10

Expression Level of Wnt5a Was Related to the Therapeutic Effects of First-Generation EGFR-TKIs.

Zhang H, Yang X, Hu F, Li C, Xu J, Nie W, Shen Y, Lou Y, Han B, Zhong H, Zhang X. Zhang H, et al. Onco Targets Ther. 2020 Jun 11;13:5387-5394. doi: 10.2147/OTT.S250024. eCollection 2020. Onco Targets Ther. 2020. PMID: 32606756 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,067 results

Search Page

Filters